Article
The rate of occurrence, healthcare resource use and costs of adverse events among metastatic non-small cell lung cancer patients treated with first- and second-generation epidermal growth factor receptor tyrosine kinase inhibitors.
Lung cancer (Amsterdam, Netherlands) - 1 Dec 2019
Subramanian Janakiraman, Fernandes Ancilla W, Laliberté François, Pavilack Melissa, DerSarkissian Maral, Duh Mei Sheng
Abstract excerpt
OBJECTIVES: Clinical trials with first- and second-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) reported severe adverse events (SAEs) in 6%-49% of patients with EGFR-mutated non-small cell lung cancer. This study describes incremental healthcare resource utilization (HRU) and costs associated with real-world management of AEs in this population, with a focus on SAEs....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.